AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Anaphase-promoting complex subunit 7

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9UJX3

UPID:

APC7_HUMAN

Alternative names:

Cyclosome subunit 7

Alternative UPACC:

Q9UJX3; Q96AC4; Q96GF4; Q9BU24; Q9NT16

Background:

Anaphase-promoting complex subunit 7 (APC7) is a pivotal component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase. This complex is instrumental in controlling mitosis and the G1 phase of the cell cycle, primarily through the mediation of 'Lys-11'-linked polyubiquitin chains. Although not essential for APC/C assembly, APC7 enhances the complex's specificity by facilitating the ubiquitination of particular substrates, including the clearance of MKI67 from constitutive heterochromatin, which is crucial for brain development.

Therapeutic significance:

APC7's involvement in Ferguson-Bonni neurodevelopmental syndrome, a disorder marked by developmental delays and intellectual impairment, underscores its potential as a therapeutic target. Understanding the role of APC7 could open doors to potential therapeutic strategies for treating this syndrome and possibly other neurodevelopmental disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.